Prescient Therapeutics Shareholder Replay 1st May 2023
Prescient Therapeutics Shareholder Briefing In this session, Prescient Therapeutics CEO and MD Steven Yatomi-Clarke discussed:...
Prescient Therapeutics Shareholder Briefing In this session, Prescient Therapeutics CEO and MD Steven Yatomi-Clarke discussed:...
CEO and MD of Prescient Therapeutics, Steven Yatomi-Clarke, held a briefing where he outlined the...
Prescient Therapeutics (ASX: PTX) managing director and chief executive officer Steven Yatomi-Clarke joins Small Caps...
Prescient Therapeutics: PTX-100 targeted cell therapy briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke gave...
Prescient Therapeutics Shareholder Briefing In this session, Prescient Therapeutics CEO and MD Steven Yatomi-Clarke discussed:...
Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously...
“It is very exciting to see PTX-100 show clinical activity in a patient population that...
A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.